Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals (MDGL) reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus Estimate of a loss of$4.12. In the year-ago quarter, the company had incurred a loss of $5.68 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.During the quarter, the company generated total revenues of$103.3 million entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved la ...